8-K current report · filed Nov 5, 2026

ANI PHARMACEUTICALS INC (ANIP) 8-K Current Report: November 5, 2026

Item EX-99.4Item 1.01Item 2.03Item 8.01Item EX-99.1Item EX-99.2Item EX-99.3ANIP overview

Short answer

ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.4 (Exhibit EX-99.4), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics.

ANI PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics
  • Facility also earmarked to refinance ANI’s existing term loans and certain Egetis indebtedness
  • Initial interest margins: 1.75% over ABR or 2.75% over adjusted term SOFR
  • Initially unsecured, becoming secured by substantially all company and certain subsidiary assets upon funding
  • Short maturity and security package increase refinancing and leverage risk if the Egetis transaction closes

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 points to Item 1.01 for the underlying borrowing or financial obligation details
  • Investor impact depends on the referenced agreement’s amount, pricing, maturity, and purpose

Item 8.01 · Other Events

  • Recommended cash offer for Egetis: SEK 5.6B, approximately $559.9M total consideration
  • Consideration: SEK 11.25 per share, SEK 65,750,817 for the Convertible, and SEK 6.99 per Warrant
  • Egetis board recommendation and 42.2% shareholder commitments materially improve transaction certainty
  • Closing requires at least 90% fully diluted tender acceptance and regulatory, governmental, and competition clearances
  • Above 90% ownership could trigger compulsory redemption and Egetis delisting from Nasdaq Stockholm

Item EX-99.1 · Exhibit EX-99.1

  • ANI is preparing a voluntary cash offer for Egetis Therapeutics at SEK 11.25 per share
  • Proposed consideration also includes SEK 65,750,817 per convertible and SEK 6.99 per warrant
  • An unnamed shareholder has irrevocably committed to tender its shares, strengthening transaction support
  • Commitment expires if the offer is not announced by November 30, 2026, or declared unconditional by March 31, 2027
  • Shareholder can withdraw if a competing bid exceeds ANI’s price by more than 5%, unless ANI matches or exceeds it

Item EX-99.2 · Exhibit EX-99.2

  • Recommended acquisition of Egetis for approximately SEK 5.6B, or $560M, financed with cash on hand and new JPMorgan debt
  • Net enterprise value approximately $434M after Egetis’ planned $190.0M PRV sale and related earn-out obligations
  • EMCITATE approved in U.S. and Europe, with over $300M peak-sales potential and patent protection into 2045
  • Offer price SEK 11.25 per share, a 27% premium to Egetis’ 60-day VWAP
  • Closing requires at least 90% shareholder acceptance and regulatory approvals, with the offer period expected November 20 to December 18, 2026

Item EX-99.3 · Exhibit EX-99.3

  • Recommended cash acquisition of Egetis for approximately SEK 5,304 million, expanding ANI’s rare-disease platform with EMCITATE
  • Offer price SEK 11.25 per share, premiums of 12.6% to last close, 27.0% to 60-day average and 48.0% to 180-day average
  • Egetis’ EMCITATE received FDA approval September 28, 2026, with U.S. launch potential and a Rare Pediatric Disease Priority Review Voucher
  • 42.2% shareholder support and unanimous Egetis board recommendation materially strengthen transaction certainty
  • Funding combines cash on hand and JPMorgan debt, with acceptance expected November 20 to December 18, 2026 and completion requiring over 90% ownership

Item EX-99.4 · Exhibit EX-99.4

  • Egetis board unanimously recommends ANI’s SEK 5,304 million cash offer, supporting ANIP’s acquisition of a commercial-stage rare-disease platform
  • Consideration: SEK 11.25 per share, SEK 65,750,817 for the EUR 3 million convertible, and SEK 6.99 per warrant
  • Offer premiums: 12.6% to last close, 27.0% to 60-day average, and 48.0% to 180-day average
  • Shareholder undertakings cover 196,127,092 shares, approximately 42.2% of outstanding shares, materially improving deal certainty
  • Completion requires over 90% ownership on a fully diluted basis and regulatory clearances, with acceptance expected from 20 November to 18 December 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANI PHARMACEUTICALS INC 8-K filings

Get the next ANIP 8-K as it lands

Follow ANIP for push alerts, or ask the research agent what this filing means.